A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B

References

• Razavi-Shearer D, Gamkrelidze I, Nguyen MH. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403. doi:10.1016/S2468-1253(18)30056-6
   PubMed Web of Science ®Google Scholar
• Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–2324. doi:10.1016/S0140-6736(18)31865-8
   PubMed Web of Science ®Google Scholar
• Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–1813. doi:10.1001/jama.2018.3795
   PubMed Web of Science ®Google Scholar
• Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169–2179 e1–e4. doi:10.1053/j.gastro.2009.03.006
   Web of Science ®Google Scholar
• Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45–52. doi:10.1016/j.jhep.2006.08.021
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599.
   PubMed Web of Science ®Google Scholar
• Hou FQ, Song LW, Yuan Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics. 2015;5(3):218–226. doi:10.7150/thno.10636
   PubMed Web of Science ®Google Scholar
• Chen H, Sun J, Zhou B, et al. Variants in STAT4 associated with cure of chronic HBV infection in HBeAg-positive patients treated with pegylated interferon-alpha. Clin Gastroenterol Hepatol. 2020;18(1):196–204 e8. doi:10.1016/j.cgh.2019.04.044
   Web of Science ®Google Scholar
• Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384(9959):2053–2063. doi:10.1016/S0140-6736(14)60220-8
   PubMed Web of Science ®Google Scholar
• Xun Z, Lin J, Yu Q, et al. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol. 2021;18(2):461–471. doi:10.1038/s41423-020-00601-8
   Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi:10.1038/nature08309
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. doi:10.1038/nature08463
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–171. doi:10.1038/ng.2521
   PubMed Web of Science ®Google Scholar
• Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45(1):72–75. doi:10.1038/ng.2483
   Web of Science ®Google Scholar
• Jiang DK, Ma XP, Wu X, et al. Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis. Sci Rep. 2015;5:16278. doi:10.1038/srep16278
   Web of Science ®Google Scholar
• Jiang DK, Wu X, Qian J, et al. Genetic variation in STAT4 predicts response to interferon-alpha therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2016;63(4):1102–1111. doi:10.1002/hep.28423
   Web of Science ®Google Scholar
• Jiang DK, Ma XP, Yu H, et al. Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B. Hepatology. 2015;62(1):118–128. doi:10.1002/hep.27794
   Web of Science ®Google Scholar
• Chen H, Sun J, Zhou B, et al. A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNalpha therapy in Chinese HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51(4):469–478. doi:10.1111/apt.15624
   Web of Science ®Google Scholar
• Junqueira C, Barbosa CRR, Costa PAC, et al. Cytotoxic CD8(+) T cells recognize and kill Plasmodium vivax-infected reticulocytes. Nat Med. 2018;24(9):1330–1336. doi:10.1038/s41591-018-0117-4
   PubMed Web of Science ®Google Scholar
• Lu CC, Wu TS, Hsu YJ, et al. NK cells kill mycobacteria directly by releasing perforin and granulysin. J Leukoc Biol. 2014;96(6):1119–1129. doi:10.1189/jlb.4A0713-363RR
   Web of Science ®Google Scholar
• Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107–1118. doi:10.1038/s41590-020-0762-x
   PubMed Web of Science ®Google Scholar
• Sun Q, Burton RL, Lucas KG. Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures. Blood. 2002;99(9):3302–3309. doi:10.1182/blood.V99.9.3302
   Web of Science ®Google Scholar
• Sparrow E, Bodman-Smith MD. Granulysin: the attractive side of a natural born killer. Immunol Lett. 2020;217:126–132. doi:10.1016/j.imlet.2019.11.005
   Web of Science ®Google Scholar
• Hata A, Zerboni L, Sommer M, et al. Granulysin blocks replication of varicella-zoster virus and triggers apoptosis of infected cells. Viral Immunol. 2001;14(2):125–133. doi:10.1089/088282401750234501
   PubMed Web of Science ®Google Scholar
• Park GH, Kim KY, Cheong JY, Cho SW, Kwack K. Association of GNLY genetic polymorphisms with chronic liver disease in a Korean population. DNA Cell Biol. 2012;31(9):1492–1498. doi:10.1089/dna.2012.1709
   Web of Science ®Google Scholar
• Hou SH, Hu J, Zhang Y, Li QL, Guo JJ. Effects of interaction between genetic variants in human leukocyte antigen DQ and granulysin genes in Chinese Han subjects infected with hepatitis B virus. Microbiol Immunol. 2015;59(4):209–218. doi:10.1111/1348-0421.12239
   Web of Science ®Google Scholar
• Sun J, Xie Q, Tan D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59(4):1283–1292. doi:10.1002/hep.26885
   PubMed Web of Science ®Google Scholar
• Liang X, Cheng J, Sun Y, et al. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol. 2015;30(4):748–755. doi:10.1111/jgh.12835
   Web of Science ®Google Scholar
• Sun J, Ma H, Xie Q, et al. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: a randomized controlled study. J Hepatol. 2016;65(4):674–682. doi:10.1016/j.jhep.2016.05.024
   Web of Science ®Google Scholar
• Hou FQ, Yin YL, Zeng LY, et al. Clinical effect and safety of pegylated interferon-alpha-2b injection (Y shape, 40 kD) in treatment of HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi. 2017;25(8):589–596.
   Google Scholar
• van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020;27(6):610–619. doi:10.1111/jvh.13272
   PubMed Web of Science ®Google Scholar
• Enomoto H, Aizawa N, Hasegawa K, et al. Possible relevance of PNPLA3 and TLL1 gene polymorphisms to the efficacy of PEG-IFN therapy for HBV-infected patients. Int J Mol Sci. 2020;21(9):3089. doi:10.3390/ijms21093089
   Web of Science ®Google Scholar
• Brouwer WP, Chan HLY, Lampertico P, et al. Genome-wide association study identifies genetic variants associated with early and sustained response to (pegylated) interferon in chronic hepatitis B patients: the GIANT-B study. Clin Infect Dis. 2019;69(11):1969–1979. doi:10.1093/cid/ciz084
   Web of Science ®Google Scholar
• Chan HLY, Messinger D, Papatheodoridis GV, et al. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48(5):547–555. doi:10.1111/apt.14862
   PubMed Web of Science ®Google Scholar
• Xie DY, Wang SM, Yang JM, et al. IFIT1 polymorphisms predict interferon-alpha treatment efficiency for hepatitis B virus infection. World J Gastroenterol. 2016;22(44):9813–9821. doi:10.3748/wjg.v22.i44.9813
   Web of Science ®Google Scholar
• Pei Y, Wang C, Yan SF, Liu LG. Past, current, and future developments of therapeutic agents for treatment of chronic hepatitis B virus infection. J Med Chem. 2017;60(15):6461–6479. doi:10.1021/acs.jmedchem.6b01442
   Web of Science ®Google Scholar
• Lampertico P, Vigano M, Colombo M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Liver Int. 2013;33(Suppl 1):157–163. doi:10.1111/liv.12064
   PubMed Web of Science ®Google Scholar
• Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34(Suppl 1):112–119. doi:10.1111/liv.12400
   PubMed Web of Science ®Google Scholar
• Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–2194. doi:10.1053/j.gastro.2020.02.058
   PubMed Web of Science ®Google Scholar
• Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2016;213(6):966–974. doi:10.1093/infdis/jiv547
   PubMed Web of Science ®Google Scholar
• Walch M, Dotiwala F, Mulik S, et al. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes. Cell. 2014;157(6):1309–1323. doi:10.1016/j.cell.2014.03.062
   Web of Science ®Google Scholar
• Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology. 2020;72(3):845–856. doi:10.1002/hep.31238
   PubMed Web of Science ®Google Scholar